ATE462973T1 - Diagnose und prävention der krebszellinvasion - Google Patents

Diagnose und prävention der krebszellinvasion

Info

Publication number
ATE462973T1
ATE462973T1 AT03763885T AT03763885T ATE462973T1 AT E462973 T1 ATE462973 T1 AT E462973T1 AT 03763885 T AT03763885 T AT 03763885T AT 03763885 T AT03763885 T AT 03763885T AT E462973 T1 ATE462973 T1 AT E462973T1
Authority
AT
Austria
Prior art keywords
prevention
cancer cell
cell invasion
diagnosis
malignant disorders
Prior art date
Application number
AT03763885T
Other languages
English (en)
Inventor
Axel Ullrich
Pjotr Knyazev
Tatjana Knyazeva
Yuri Cheburkin
Peter Vajkoczy
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE462973T1 publication Critical patent/ATE462973T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03763885T 2002-07-17 2003-07-17 Diagnose und prävention der krebszellinvasion ATE462973T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02015944A EP1382969A1 (de) 2002-07-17 2002-07-17 Diagnose und Behandlung der Invasion von Krebszellen
PCT/EP2003/007786 WO2004008147A2 (en) 2002-07-17 2003-07-17 Diagnosis and prevention of cancer cell invasion

Publications (1)

Publication Number Publication Date
ATE462973T1 true ATE462973T1 (de) 2010-04-15

Family

ID=29762643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763885T ATE462973T1 (de) 2002-07-17 2003-07-17 Diagnose und prävention der krebszellinvasion

Country Status (11)

Country Link
US (2) US8277802B2 (de)
EP (4) EP1382969A1 (de)
JP (2) JP5419316B2 (de)
CN (2) CN102349997A (de)
AT (1) ATE462973T1 (de)
AU (2) AU2003250984B2 (de)
CA (1) CA2493111C (de)
DE (1) DE60331921D1 (de)
DK (1) DK1530724T3 (de)
ES (1) ES2343950T3 (de)
WO (1) WO2004008147A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
EP1171771B1 (de) 1999-04-09 2005-06-29 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
EP1563094A4 (de) * 2002-10-29 2007-04-25 Rigel Pharmaceuticals Inc Modulatoren der angiogenese und tumorigenese
EP1899482A2 (de) * 2005-04-07 2008-03-19 Novartis Vaccines and Diagnostics, Inc. Ddr2 in der diagnose, dem nachweis und der behandlung von krebs
IN2014DN10515A (de) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
EP2114983B8 (de) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl-tyrosinkinasehemmer sowie verfahren zu ihrer herstellung und verwendung
US20100255004A1 (en) * 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
WO2009005813A1 (en) * 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
AU2008317404B2 (en) * 2007-10-19 2014-12-18 Cell Signaling Technology, Inc. Cancer classification and methods of use
CN101939336B (zh) * 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
TW200936160A (en) * 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
SG174356A1 (en) * 2009-03-13 2011-10-28 Bergen Teknologioverforing As Methods using axl as a biomarker of epithelial-to-mesnchymal transition
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
MX2011011825A (es) * 2009-05-11 2011-12-06 U3 Pharma Gmbh Anticuerpos humanizados para axl.
EP2270053A1 (de) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
CN102459344A (zh) * 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA2786149C (en) * 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
WO2011159980A1 (en) 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use
EP2606364A4 (de) * 2010-08-19 2014-04-16 Howard Florey Inst Tam-rezeptoren und tam-rezeptorliganden in der erfassung und modulation neuropathologischer krankheiten
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
US20130295578A1 (en) * 2011-01-10 2013-11-07 Trustees Of Dartmouth College Methods for screening for drug resistance in cancer treatment
WO2012175692A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US9499856B2 (en) 2012-04-02 2016-11-22 The Board Institute, Inc. DDR2 mutations in squamous cell lung cancer
PT2931265T (pt) 2012-12-14 2018-04-16 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6195716B2 (ja) * 2013-02-15 2017-09-13 富士レビオ株式会社 抗癌剤耐性診断マーカー
WO2015080047A1 (ja) 2013-11-27 2015-06-04 株式会社カネカ 細胞培養培地及びそれを用いた培養方法
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
CA2935266C (en) * 2014-01-03 2022-02-01 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
JP2017205021A (ja) * 2014-09-26 2017-11-24 Jsr株式会社 初代癌細胞のスフェロイド作製方法、スフェロイド、スクリーニング方法、及び、診断方法
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
AU2015366213B2 (en) 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
KR102606938B1 (ko) 2016-04-15 2023-11-29 바이오아트라, 인코퍼레이티드 항 Axl항체 및 이의 면역접합체와 이것들의 용도
EP3455261B1 (de) 2016-05-13 2022-08-03 BioAtla, Inc. Anti-ror2-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
US12187801B2 (en) 2017-01-18 2025-01-07 Exuma Biotech Corp. Chimeric antigen receptors against AXL or ROR2 and methods of use thereof
KR102357045B1 (ko) 2017-03-31 2022-01-28 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 형태계측 시험
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7029745B2 (ja) * 2017-12-05 2022-03-04 国立大学法人金沢大学 膠芽腫マーカー及びその使用
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
CN115916344A (zh) 2020-04-08 2023-04-04 卑尔根生物股份公司 用于抗病毒疗法的axl抑制剂
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE4110405A1 (de) * 1991-03-28 1992-10-01 Birchmeier Walter Prof Dr Verfahren zum nachweis der differenzierung und der invasivitaet von karzinomzellen
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
ES2315435T3 (es) 1996-08-12 2009-04-01 Celgene Corporation Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
WO2000076309A2 (en) * 1999-06-10 2000-12-21 D.Collen Research Foundation Vzw Non-human transgenic animals deficient in gas6 function and their use
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU1339701A (en) * 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
US20020068709A1 (en) * 1999-12-23 2002-06-06 Henrik Orum Therapeutic uses of LNA-modified oligonucleotides
WO2001078778A1 (en) * 2000-04-13 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie (Vib) USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE
AU2002234799A1 (en) 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
EP2003196A3 (de) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Krebs

Also Published As

Publication number Publication date
AU2009251103B2 (en) 2013-09-05
DK1530724T3 (da) 2010-08-02
JP2011024580A (ja) 2011-02-10
JP2005532805A (ja) 2005-11-04
US20050186571A1 (en) 2005-08-25
US20130084300A1 (en) 2013-04-04
WO2004008147A3 (en) 2004-05-27
EP1530724A2 (de) 2005-05-18
EP2267454A3 (de) 2011-03-30
EP1382969A1 (de) 2004-01-21
CN102349997A (zh) 2012-02-15
AU2009251103A1 (en) 2010-01-21
EP1530724B1 (de) 2010-03-31
JP5419316B2 (ja) 2014-02-19
EP2228654A2 (de) 2010-09-15
AU2003250984A1 (en) 2004-02-02
US8277802B2 (en) 2012-10-02
CA2493111A1 (en) 2004-01-22
CN1739030A (zh) 2006-02-22
CA2493111C (en) 2016-07-05
EP2228654A3 (de) 2011-01-05
AU2003250984B2 (en) 2009-10-08
ES2343950T3 (es) 2010-08-13
DE60331921D1 (de) 2010-05-12
WO2004008147A2 (en) 2004-01-22
EP2267454A2 (de) 2010-12-29

Similar Documents

Publication Publication Date Title
ATE462973T1 (de) Diagnose und prävention der krebszellinvasion
EP1578380A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003087831A3 (en) Proteins involved in breast cancer
EP2006298A3 (de) Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
EP1578371A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EP1515982A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
ATE413902T1 (de) Patientenüberwachungssystem
ATE491385T1 (de) Schutzhülle für ein medizinprodukt und herstellungsverfahren dafür
EP1409549A4 (de) Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
DE602005013811D1 (de) Behandlung von fettsucht und verbundenen erkrankungen
EP1583504A4 (de) Verfahren und zusammensetzungen für diagnose, prognose und behandlung von krebs
IL162201A0 (en) New methods for diagnosis and treatment of tumours
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
EP1546182A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
EP1608967A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
PT1606233E (pt) Derivados de esteres lipidicos de nucleotidos
NO20054049D0 (no) Fremgangsmate for diagnose og behandling.
WO2004005540A3 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties